Company now focused on activities leading to faster commercial status MONTREAL, July 2, 2024 /CNW/ - ChitogenX Inc., (CSE:CHGX) (OTCQB:CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today reported its financial results and highlights for the first quarter 2025 ended April 30, 2024. ''Our main priorities for fiscal 2025 remains securing the required capital to fund our operations and delivering on the anticipated corporate milestones. We believe our two latest programs, burn healing and skin repair will play a key role in facilitating the achievement of these objectives", said Pierre Laurin, President, and interim CEO. "We are currently evaluating opportunities for fast-track regulatory programs with potential 510(k) pre-market submissions in the US and commercial readiness in other jurisdictions. We look forward to providing more details on our plans to take full advantage of the broad clinical and commercial opportunities now available to the Company''.  Commenting on the first ...